Kelsey Roe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kelsey Roe has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Daniela Giordano
Department of Immunology, University of Washington , Seattle, WA 98109
4 shared publications - Edward A. Clark
Department of Immunology, University of Washington , Seattle, WA 98109
4 shared publications Kevin E Draves
Department of Immunology, University of Washington , Seattle, WA 98109
2 shared publicationsKevin E. Draves
Department of Immunology, University of Washington, Seattle, Washington, United States of America
2 shared publicationsLucy B. Young
Department of Immunology, University of Washington, Seattle, Washington, United States of America
2 shared publicationsMichael Gale
Department of Immunology, University of Washington, Seattle, Washington, United States of America
2 shared publications
Latest Publications
- Open Access
- 12 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (24) , eaeb7633
B cell αv integrin regulates tissue specialization and clonal expansion of lung germinal center and memory B cells after viral infection
Lung-resident B cells are increasingly recognized as key contributors to protective immunity against respiratory viruses, yet the mechanisms that govern their generation and specialization remain poorly understood. Here, we identify B cell–intrinsic αv integrin as a critical negative regulator of germinal center (GC) dynamics and memory B cell formation in the lung following influenza A virus infection. Using B cell–specific αv knockout mice, we show that loss of B cell αv integrin leads to persistent GC activity within the inducible bronchus-associated lymphoid tissue and expansion of lung-resident memory B cells, including IgA + and cross-reactive B cells capable of recognizing heterologous influenza variants. Single-cell transcriptomic and B cell receptor sequence analyses reveal that αv restricts clonal expansion and antigenic diversification of GC and memory B cells in the lung, but not in draining lymph nodes, indicating a spatially restricted mechanism of mucosal B cell regulation. These findings position αv integrin as a key checkpoint that constrains local mucosal B cell evolution and suggest previously unexplored strategies to improve mucosal vaccine efficacy by enhancing GC activity directly in the lung.
- 12 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (24) , eaeb7633
Open AccessB cell αv integrin regulates tissue specialization and clonal expansion of lung germinal center and memory B cells after viral infection
Lung-resident B cells are increasingly recognized as key contributors to protective immunity against respiratory viruses, yet the mechanisms that govern their generation and specialization remain poorly understood. Here, we identify B cell–intrinsic αv integrin as a critical negative regulator of germinal center (GC) dynamics and memory B cell formation in the lung following influenza A virus infection. Using B cell–specific αv knockout mice, we show that loss of B cell αv integrin leads to persistent GC activity within the inducible bronchus-associated lymphoid tissue and expansion of lung-resident memory B cells, including IgA + and cross-reactive B cells capable of recognizing heterologous influenza variants. Single-cell transcriptomic and B cell receptor sequence analyses reveal that αv restricts clonal expansion and antigenic diversification of GC and memory B cells in the lung, but not in draining lymph nodes, indicating a spatially restricted mechanism of mucosal B cell regulation. These findings position αv integrin as a key checkpoint that constrains local mucosal B cell evolution and suggest previously unexplored strategies to improve mucosal vaccine efficacy by enhancing GC activity directly in the lung.
- Open Access
- 7 February 2020
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 204 (6) , 1508-1520
BAFF Produced by Neutrophils and Dendritic Cells Is Regulated Differently and Has Distinct Roles in Antibody Responses and Protective Immunity against West Nile Virus
B cell activating factor (BAFF) is essential for B cells to develop and respond to Ags. Dysregulation of BAFF contributes to the development of some autoimmune diseases and malignancies. Little is known about when, where, and how BAFF is produced in vivo and about which BAFF-producing cells contribute to B cell responses. To better understand BAFF functions, we created BAFF reporter (BAFF-RFP) mice and Baff floxed (Bafffl/fl) mice. Splenic and bone marrow neutrophils (Nphs) from BAFF-RFP mice expressed the highest constitutive levels of BAFF; other myeloid subsets, including conventional dendritic cells (cDCs) and monocyte (MO) subsets, expressed lower levels. Treatment of BAFF-RFP mice with polyinosinic:polycytidylic acid increased BAFF expression in splenic Ly6Chi inflammatory MOs, CD11bhi activated NK subset, and in bone marrow myeloid precursors. Postinfection with West Nile virus (WNV), BAFF increased in CD8− cDCs and Nphs, and BAFF+ CD11bhi NK cells expanded in draining lymph nodes. The cell- and tissue-specific increases in BAFF expression were dependent on type I IFN signaling. MAVS also was required or contributed to BAFF expression in dendritic cell and MO subsets, respectively. Mice with deletion of Baff in either cDCs or Nphs had reduced Ab responses after NP-Ficoll immunization; thus, BAFF produced by both cDCs and Nphs contributes to T cell–independent Ab responses. Conversely, mice with a cDC Baff deficiency had increased mortality after WNV infection and decreased WNV-specific IgG and neutralizing Ab responses. BAFF produced by Nphs and cDCs is regulated differently and has key roles in Ab responses and protective immunity.
- 7 February 2020
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 204 (6) , 1508-1520
Open AccessBAFF Produced by Neutrophils and Dendritic Cells Is Regulated Differently and Has Distinct Roles in Antibody Responses and Protective Immunity against West Nile Virus
B cell activating factor (BAFF) is essential for B cells to develop and respond to Ags. Dysregulation of BAFF contributes to the development of some autoimmune diseases and malignancies. Little is known about when, where, and how BAFF is produced in vivo and about which BAFF-producing cells contribute to B cell responses. To better understand BAFF functions, we created BAFF reporter (BAFF-RFP) mice and Baff floxed (Bafffl/fl) mice. Splenic and bone marrow neutrophils (Nphs) from BAFF-RFP mice expressed the highest constitutive levels of BAFF; other myeloid subsets, including conventional dendritic cells (cDCs) and monocyte (MO) subsets, expressed lower levels. Treatment of BAFF-RFP mice with polyinosinic:polycytidylic acid increased BAFF expression in splenic Ly6Chi inflammatory MOs, CD11bhi activated NK subset, and in bone marrow myeloid precursors. Postinfection with West Nile virus (WNV), BAFF increased in CD8− cDCs and Nphs, and BAFF+ CD11bhi NK cells expanded in draining lymph nodes. The cell- and tissue-specific increases in BAFF expression were dependent on type I IFN signaling. MAVS also was required or contributed to BAFF expression in dendritic cell and MO subsets, respectively. Mice with deletion of Baff in either cDCs or Nphs had reduced Ab responses after NP-Ficoll immunization; thus, BAFF produced by both cDCs and Nphs contributes to T cell–independent Ab responses. Conversely, mice with a cDC Baff deficiency had increased mortality after WNV infection and decreased WNV-specific IgG and neutralizing Ab responses. BAFF produced by Nphs and cDCs is regulated differently and has key roles in Ab responses and protective immunity.
- Open Access
- 1 October 2019
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 203 (7) , 1715-1729
Targeting Antigens to CD180 but Not CD40 Programs Immature and Mature B Cell Subsets to Become Efficient APCs
Targeting Ags to the CD180 receptor activates both B cells and dendritic cells (DCs) to become potent APCs. After inoculating mice with Ag conjugated to an anti-CD180 Ab, B cell receptors were rapidly internalized. Remarkably, all B cell subsets, including even transitional 1 B cells, were programed to process, present Ag, and stimulate Ag-specific CD4+ T cells. Within 24–48 hours, Ag-specific B cells were detectable at T–B borders in the spleen; there, they proliferated in a T cell–dependent manner and induced the maturation of T follicular helper (TFH) cells. Remarkably, immature B cells were sufficient for the maturation of TFH cells after CD180 targeting: TFH cells were induced in BAFFR−/− mice (with only transitional 1 B cells) and not in μMT mice (lacking all B cells) following CD180 targeting. Unlike CD180 targeting, CD40 targeting only induced DCs but not B cells to become APCs and thus failed to efficiently induce TFH cell maturation, resulting in slower and lower-affinity IgG Ab responses. CD180 targeting induces a unique program in Ag-specific B cells and to our knowledge, is a novel strategy to induce Ag presentation in both DCs and B cells, especially immature B cells and thus has the potential to produce a broad range of Ab specificities. This study highlights the ability of immature B cells to present Ag to and induce the maturation of cognate TFH cells, providing insights toward vaccination of mature B cell–deficient individuals and implications in treating autoimmune disorders. Key Points CD180 Ag targeting facilitates Ag presentation by B cells to CD4+ T cells. Immature B cells are sufficient for TFH cell maturation. Compared with CD180, CD40 targeting induces slower and lower-affinity IgG responses.
- 1 October 2019
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 203 (7) , 1715-1729
Open AccessTargeting Antigens to CD180 but Not CD40 Programs Immature and Mature B Cell Subsets to Become Efficient APCs
Targeting Ags to the CD180 receptor activates both B cells and dendritic cells (DCs) to become potent APCs. After inoculating mice with Ag conjugated to an anti-CD180 Ab, B cell receptors were rapidly internalized. Remarkably, all B cell subsets, including even transitional 1 B cells, were programed to process, present Ag, and stimulate Ag-specific CD4+ T cells. Within 24–48 hours, Ag-specific B cells were detectable at T–B borders in the spleen; there, they proliferated in a T cell–dependent manner and induced the maturation of T follicular helper (TFH) cells. Remarkably, immature B cells were sufficient for the maturation of TFH cells after CD180 targeting: TFH cells were induced in BAFFR−/− mice (with only transitional 1 B cells) and not in μMT mice (lacking all B cells) following CD180 targeting. Unlike CD180 targeting, CD40 targeting only induced DCs but not B cells to become APCs and thus failed to efficiently induce TFH cell maturation, resulting in slower and lower-affinity IgG Ab responses. CD180 targeting induces a unique program in Ag-specific B cells and to our knowledge, is a novel strategy to induce Ag presentation in both DCs and B cells, especially immature B cells and thus has the potential to produce a broad range of Ab specificities. This study highlights the ability of immature B cells to present Ag to and induce the maturation of cognate TFH cells, providing insights toward vaccination of mature B cell–deficient individuals and implications in treating autoimmune disorders. Key Points CD180 Ag targeting facilitates Ag presentation by B cells to CD4+ T cells. Immature B cells are sufficient for TFH cell maturation. Compared with CD180, CD40 targeting induces slower and lower-affinity IgG responses.
- Open Access
- 26 June 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (6) , e0218928
Dendritic cell-associated MAVS is required to control West Nile virus replication and ensuing humoral immune responses
Mitochondrial antiviral signaling protein (MAVS) is a critical innate immune signaling protein that directs the actions of the RIG-I-like receptor (RLR) signaling pathway of RNA virus recognition and initiation of anti-viral immunity against West Nile virus (WNV). In the absence of MAVS, mice die more rapidly after infection with the pathogenic WNV-Texas (TX) strain, but also produce elevated WNV-specific IgG concomitant with increased viral burden. Here we investigated whether there was a B cell intrinsic role for MAVS during the development of protective humoral immunity following WNV infection. MAVS-/- mice survived infection from the non-pathogenic WNV-Madagascar (MAD) strain, with limited signs of disease. Compared to wildtype (WT) controls, WNV-MAD-infected MAVS-/- mice had elevated serum neutralizing antibodies, splenic germinal center B cells, plasma cells and effector T cells. We found that when rechallenged with the normally lethal WNV-TX, MAVS-/- mice previously infected with WNV-MAD were protected from disease. Thus, protective humoral and cellular immune responses can be generated in absence of MAVS. Mice with a conditional deletion of MAVS only in CD11c+ dendritic cells phenocopied MAVS whole body knockout mice in their humoral responses to WNV-MAD, displaying elevated virus titers and neutralizing antibodies. Conversely, a B cell-specific deletion of MAVS had no effect on immune responses to WNV-MAD compared to WT controls. Thus, MAVS in dendritic cells is required to control WNV replication and thereby regulate downstream humoral immune responses.
- 26 June 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (6) , e0218928
Open AccessDendritic cell-associated MAVS is required to control West Nile virus replication and ensuing humoral immune responses
Mitochondrial antiviral signaling protein (MAVS) is a critical innate immune signaling protein that directs the actions of the RIG-I-like receptor (RLR) signaling pathway of RNA virus recognition and initiation of anti-viral immunity against West Nile virus (WNV). In the absence of MAVS, mice die more rapidly after infection with the pathogenic WNV-Texas (TX) strain, but also produce elevated WNV-specific IgG concomitant with increased viral burden. Here we investigated whether there was a B cell intrinsic role for MAVS during the development of protective humoral immunity following WNV infection. MAVS-/- mice survived infection from the non-pathogenic WNV-Madagascar (MAD) strain, with limited signs of disease. Compared to wildtype (WT) controls, WNV-MAD-infected MAVS-/- mice had elevated serum neutralizing antibodies, splenic germinal center B cells, plasma cells and effector T cells. We found that when rechallenged with the normally lethal WNV-TX, MAVS-/- mice previously infected with WNV-MAD were protected from disease. Thus, protective humoral and cellular immune responses can be generated in absence of MAVS. Mice with a conditional deletion of MAVS only in CD11c+ dendritic cells phenocopied MAVS whole body knockout mice in their humoral responses to WNV-MAD, displaying elevated virus titers and neutralizing antibodies. Conversely, a B cell-specific deletion of MAVS had no effect on immune responses to WNV-MAD compared to WT controls. Thus, MAVS in dendritic cells is required to control WNV replication and thereby regulate downstream humoral immune responses.
- Open Access
- 27 November 2017
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 13 (11) , e1006743
Protection of mice deficient in mature B cells from West Nile virus infection by passive and active immunization
B cell activating factor receptor (BAFFR)-/- mice have a profound reduction in mature B cells, but unlike μMT mice, they have normal numbers of newly formed, immature B cells. Using a West Nile virus (WNV) challenge model that requires antibodies (Abs) for protection, we found that unlike wild-type (WT) mice, BAFFR-/- mice were highly susceptible to WNV and succumbed to infection within 8 to 12 days after subcutaneous virus challenge. Although mature B cells were required to protect against lethal infection, infected BAFFR-/- mice had reduced WNV E-specific IgG responses and neutralizing Abs. Passive transfer of immune sera from previously infected WT mice rescued BAFFR-/- and fully B cell-deficient μMT mice, but unlike μMT mice that died around 30 days post-infection, BAFFR-/- mice survived, developed WNV-specific IgG Abs and overcame a second WNV challenge. Remarkably, protective immunity could be induced in mature B cell-deficient mice. Administration of a WNV E-anti-CD180 conjugate vaccine 30 days prior to WNV infection induced Ab responses that protected against lethal infection in BAFFR-/- mice but not in μMT mice. Thus, the immature B cells present in BAFFR-/- and not μMT mice contribute to protective antiviral immunity. A CD180-based vaccine may promote immunity in immunocompromised individuals. Many individuals including infants, the elderly and the immunocompromised do not develop protective immunity after immunization with current vaccines. Thus, new vaccine strategies are needed to overcome underlying immune deficiencies and mediate protection. In this study, we examined whether it was possible to induce protective immunity even in BAFFR-deficient mice that genetically lack mature B cells but still make immature B cells. We infected mice with the flavivirus, West Nile virus (WNV), since elderly and immunocompromised individuals are at greatest risk to develop severe neurological disease with this virus. As expected, the BAFFR-deficient mice died within 12 days of infection, similar to mice lacking all B cells. Unexpectedly, and unlike mice missing all B cells, BAFFR-deficient mice could be protected by passively administering immune sera or with a vaccine that can program immature B cells to make antibodies. Thus, immature B cells can play a role in protecting individuals from WNV infection, and accordingly, it is possible to design vaccines that activate these cells to develop protective immunity. These findings may be relevant for developing vaccines that can protect infants, the elderly and immunocompromised patients.
- 27 November 2017
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 13 (11) , e1006743
Open AccessProtection of mice deficient in mature B cells from West Nile virus infection by passive and active immunization
B cell activating factor receptor (BAFFR)-/- mice have a profound reduction in mature B cells, but unlike μMT mice, they have normal numbers of newly formed, immature B cells. Using a West Nile virus (WNV) challenge model that requires antibodies (Abs) for protection, we found that unlike wild-type (WT) mice, BAFFR-/- mice were highly susceptible to WNV and succumbed to infection within 8 to 12 days after subcutaneous virus challenge. Although mature B cells were required to protect against lethal infection, infected BAFFR-/- mice had reduced WNV E-specific IgG responses and neutralizing Abs. Passive transfer of immune sera from previously infected WT mice rescued BAFFR-/- and fully B cell-deficient μMT mice, but unlike μMT mice that died around 30 days post-infection, BAFFR-/- mice survived, developed WNV-specific IgG Abs and overcame a second WNV challenge. Remarkably, protective immunity could be induced in mature B cell-deficient mice. Administration of a WNV E-anti-CD180 conjugate vaccine 30 days prior to WNV infection induced Ab responses that protected against lethal infection in BAFFR-/- mice but not in μMT mice. Thus, the immature B cells present in BAFFR-/- and not μMT mice contribute to protective antiviral immunity. A CD180-based vaccine may promote immunity in immunocompromised individuals. Many individuals including infants, the elderly and the immunocompromised do not develop protective immunity after immunization with current vaccines. Thus, new vaccine strategies are needed to overcome underlying immune deficiencies and mediate protection. In this study, we examined whether it was possible to induce protective immunity even in BAFFR-deficient mice that genetically lack mature B cells but still make immature B cells. We infected mice with the flavivirus, West Nile virus (WNV), since elderly and immunocompromised individuals are at greatest risk to develop severe neurological disease with this virus. As expected, the BAFFR-deficient mice died within 12 days of infection, similar to mice lacking all B cells. Unexpectedly, and unlike mice missing all B cells, BAFFR-deficient mice could be protected by passively administering immune sera or with a vaccine that can program immature B cells to make antibodies. Thus, immature B cells can play a role in protecting individuals from WNV infection, and accordingly, it is possible to design vaccines that activate these cells to develop protective immunity. These findings may be relevant for developing vaccines that can protect infants, the elderly and immunocompromised patients.